PAVmed Inc., a diversified commercial-stage medical technology company, released its first quarter 2025 financial results. The company reported a non-GAAP adjusted loss of approximately $0.9 million, translating to $(0.07) per common share. This adjustment considers stock-based compensation and other non-cash income and expenses. As of March 31, 2025, PAVmed's cash and cash equivalents increased to $2.7 million, up from $1.2 million at the end of the previous year, December 31, 2024. In addition to the financial results, PAVmed provided significant business updates. Lucid, one of its subsidiaries, secured capital to extend its financial runway past key upcoming reimbursement milestones, ending the first quarter with over $40 million in proforma cash. Another subsidiary, Veris Health, completed its first-quarter financing and resumed development of an implantable physiological monitor. Veris is also set to launch its first commercial partnership with a major cancer center soon. PAVmed is actively seeking to leverage its infrastructure to expand into the biopharma sector and is evaluating clinical and late preclinical stage assets. The company's strategic vision is to operate as a diversified commercial life sciences entity with multiple independently-financed subsidiaries under a shared services model.